Who’s Going to Antibody Engineering 2026

Dec 13–16, 2026 San Diego, CA ~900 attendees Website

168 companies and 131 speakers at Antibody Engineering 2026, a ~900-person, mostly biopharma meeting of antibody and protein engineers. As of Nov 10, 2026.

Format
Topic
Top represented
Showing 1–10 of 168 organizations
OrganizationAntibody Engineering 2026 Attendance
Xencor
Pasadena, CA
Biotech
Develops engineered antibodies using its XmAb Fc and bispecific technologies, for cancer and autoimmune diseases.
Chair
Sun Dec 13
1:00pm–1:15pm
Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen
Talk
Sun Dec 13
4:15pm–5:00pm
Moderated Panel Discussion with Session Speakers
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Amgen
Chair
Mon Dec 14
8:00am–8:05am
Co-Chairs' Welcome and Opening Remarks
Keynote Presentations - Livestream · with Gyes
Talk
Mon Dec 14
10:55am–11:30am
Jim Huston Science Talent Award and Presentation
Keynote Presentations - Livestream · with Dana-Farber Cancer Institute, Johnson & Johnson
Chair
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 2: Engineering Antibody Interfaces: Unlocking New Biology · with Dualitas Therapeutics
Talk
Wed Dec 16
9:15am–9:45am
XenLock™ Fab domains for controlled heavy-light chain pairing in native-like 1+1 bispecific antibodies with extended half-life
Redesigned antibody arms that pair only with their intended partner, used to build two-target antibodies that last longer in blood.
Bispecifics & multispecifics
AstraZeneca
Cambridge, United Kingdom
Large pharma
Global pharmaceutical company developing antibodies, antibody-drug conjugates and multispecifics in oncology and other diseases.
Talk
Sun Dec 13
11:00am–11:45am
Career Path/Experiences Panel Discussion
Early Career Scientist Session · with Macaw Therapeutics, Genentech, Adaxion Therapeutics
Keynote
Mon Dec 14
10:20am–10:55am
From Insight to Impact: Translational Medicine as a Driver of ADC Clinical Success and Future Innovation
Why finding biological markers of response early helps antibodies carrying a cell-killing drug succeed in patients.
ADCs & conjugates
Talk
Wed Dec 16
10:30am–11:00am
CD8-Guided T Cell Engager with Potent Preclinical Efficacy and Superior Therapeutic Index
An antibody that pulls killer T cells onto liver cancer cells while rousing fewer of the T cells that drive dangerous immune reactions.
Chair
Wed Dec 16
2:10pm–2:15pm
Co-Chairs' Remarks
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms · with Washington University School of Medicine
Talk
Wed Dec 16
2:15pm–2:45pm
Expanding the Toolbox: Non-natural Amino Acids Enable Development of a CD30 Dual-payload ADC
Track 1: Beyond Classic ADCs: Novel Payloads, Modalities & Mechanisms
Amgen
Thousand Oaks, CA
Large pharma
Global biopharmaceutical company developing and manufacturing biologic medicines, including bispecific T-cell engagers.
Chair
Sun Dec 13
1:00pm–1:15pm
Co-Chairs' Remarks: From Discovery to IND: What Matters Most and How to Get it Right
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
Talk
Sun Dec 13
1:15pm–1:45pm
Developability-Guided Generative Biology for Therapeutic Protein Engineering
Designing new therapeutic proteins by computer while checking from the start that they can be made and purified.
AI & computational design
Talk
Sun Dec 13
4:15pm–5:00pm
Moderated Panel Discussion with Session Speakers
Workshop 1: From Discovery to IND: What Matters Most and How to Get it Right · with Xencor
Talk
Mon Dec 14
5:45pm–6:15pm
Induced Proximity and Next-Generation Antibody Therapeutics
Track 2: Engineering Solutions for Accessing Difficult Targets
Bispecifics & multispecifics
Genentech
South San Francisco, CA
Large pharma
Biotechnology company and Roche Group member that discovers, develops and markets antibody and other medicines.
Talk
Sun Dec 13
11:00am–11:45am
Career Path/Experiences Panel Discussion
Early Career Scientist Session · with Macaw Therapeutics, AstraZeneca, Adaxion Therapeutics
Talk
Mon Dec 14
2:30pm–3:00pm
Dissecting the Mechanisms of Action of PROTABs: Insights into Designing Antibody-Based Protein Degraders
How the shape of antibody binding decides whether a target protein on the cell surface is actually destroyed.
Bispecifics & multispecifics
Chair
Tue Dec 15
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Advanced In Vivo Approaches to Antibody Discovery · with Johnson & Johnson
Talk
Tue Dec 15
8:15am–8:45am
From COVID to Cancer: LNP-mRNA as an Antigen Format for Antibody Discovery Against Challenging Membrane Proteins
Immunizing animals with mRNA packaged in tiny fat particles, so their antibodies recognize proteins embedded in cell membranes.
Protein engineering
Johnson & Johnson
New Brunswick, NJ
Large pharma
Healthcare company whose Innovative Medicine segment develops antibodies, bispecifics and other medicines.
Talk
Sun Dec 13
2:15pm–2:45pm
Format Matters: Biophysical Characterization and Developability of Complex Biotherapeutics
How a molecule's overall shape changes whether it can be made into a drug, across many measured antibody formats.
Talk
Mon Dec 14
10:55am–11:30am
Jim Huston Science Talent Award and Presentation
Keynote Presentations - Livestream · with Xencor, Dana-Farber Cancer Institute
Chair
Tue Dec 15
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Advanced In Vivo Approaches to Antibody Discovery · with Genentech
Regeneron
Tarrytown, NY
Large pharma
Biotechnology company that discovers, develops and markets antibody medicines, including bispecific antibodies, using its VelocImmune mouse platform.
Talk
Sun Dec 13
3:45pm–4:15pm
From Molecule Design to Approved Regimens: A Clinical Pharmacology Perspective on Dose Selection for Next-Generation Biologics
How measurements of drug levels and effects in the body guide the first human dose and the final approved dosing schedule.
Talk
Mon Dec 14
5:15pm–5:45pm
Targeting IgE Responses
Track 2: Engineering Solutions for Accessing Difficult Targets
Beyond oncology
Chair
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Rondo Therapeutics
University of Southampton
Southampton, United Kingdom
Academic
Public research university whose Centre for Cancer Immunology works on antibody immunotherapy and Fc receptor biology.
Chair
Mon Dec 14
2:25pm–2:30pm
Co-Chairs’ Remarks
Track 2: Engineering Solutions for Accessing Difficult Targets · with Macaw Therapeutics
Talk
Mon Dec 14
4:45pm–5:15pm
Disulfide Engineering of Immunostimulatory Antibodies for Augmented Receptor Agonism and Immune Cell Stimulation
Adding chemical bridges between an antibody's two arms to lock its shape and make it switch on immune cells more strongly.
Protein engineering
Chair
Tue Dec 15
8:10am–8:15am
Co-Chairs' Remarks
Track 2: Antibody Engineering for Proximity-Based Approaches · with Chai Discovery
Discovery platformsGold sponsor
Provides ATX transgenic mice, display libraries and discovery services for antibodies and other drug modalities to drug developers.
Booth
Exhibiting at Booth 220
Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm
Talk
Mon Dec 14
1:45pm–2:15pm
ATX-Gx Select: A New Mouse Strain That Can Identify Antigen Experienced B Cells in Situ to Facilitate Antibody Drug Discovery for Complex Therapeutic Targets
New transgenic mouse strains that fluorescently mark antigen-experienced B cells, so antibodies against hard targets can be found without making the target protein.
Antibody discovery
Talk
Wed Dec 16
7:30am–8:00am
VHH and VLL Discovery Using ATX Transgenic Animals and Yeast Displayed Libraries
Finding tiny single-piece human antibodies, using engineered mice and yeast-grown libraries, that can reach hidden pockets on a target.
Antibody discovery
RT
Biotech
Develops bispecific T cell engagers, including co-stimulatory CD28 bispecifics, for solid tumors.
Chair
Sun Dec 13
9:00am–9:10am
Session Co-Chair Welcome and Opening Remarks
Short research talks by scientists within ten years of their graduate degree, plus career advice and time to meet peers.
with Chai Discovery
Chair
Tue Dec 15
2:25pm–2:30pm
Co-Chairs’ Remarks
Track 1: Engineering and Biological Principles for Cell Engagers · with National Cancer Institute
Talk
Tue Dec 15
2:30pm–3:00pm
Combination of Signal 1 and Signal 2 T Cell Engagers for Treatment of Ovarian Cancer
Pairing two antibodies that give T cells both of the signals they need, aiming at ovarian cancer that no longer responds to platinum drugs.
Chair
Wed Dec 16
8:10am–8:15am
Co-Chairs’ Remarks
Track 1: Beyond Bispecifics: Next Wave of Tri- & Multi-Specific Abs · with Regeneron
Twist Bioscience
South San Francisco, CA
Reagents & consumablesEvent partner
Synthetic DNA company whose biopharma unit provides antibody libraries and antibody discovery and optimization services.
Booth
Exhibiting at Booth 200
Mon, Dec 144:00pm–4:45pmTue, Dec 159:45am–4:45pm
Talk
Mon Dec 14
12:15pm–1:15pm
Scaling Wet-Lab Validation for AI-based Biologic Discovery
Why lab testing has become the bottleneck for AI antibody design, and how a shared model platform from Eli Lilly connects to it.
with Eli Lilly
AI & computational designAntibody discovery
Talk
Tue Dec 15
1:40pm–2:00pm
Screening in the Format You’ll Develop In: Cell-Free Expression of Full-Length IgG
Making full-length antibodies without cells at screening scale, and how their binding compares with the same antibodies made in mammalian cells.
Antibody discovery
Talk
Wed Dec 16
7:30am–8:00am
Engineering for Better Bispecifics: Introducing the B-Body® Platform
A two-target antibody design meant to assemble reliably, avoiding low yields and hard purification when production scales up.
Bispecifics & multispecificsDevelopability & CMC

Explore the full Antibody Engineering 2026 dataset

Get in-depth attendee and institution profiles and research, to plan your meetings in San Diego. Leave your work email and we’ll be in touch.

Privacy

Download the full Antibody Engineering 2026 CSV

Leave your work email and we’ll be in touch. The CSV adds attendee names, roles and contact details to the company and session data shown here.

Privacy

Find buyers from companies at Antibody Engineering 2026

Tell us what you sell and we’ll find the people at these companies most likely to buy it.

  • Who to contact
  • Their contact info
  • What to say
  • Free, no sign-up

When and where is Antibody Engineering 2026?

Antibody Engineering & Therapeutics 2026 runs December 13–16, 2026, at Marriott Marquis San Diego Marina in San Diego, CA.

What are the Antibody Engineering 2026 exhibit hall hours?

The exhibit hall is open Mon, Dec 14, 4:00pm–4:45pm; Tue, Dec 15, 9:45am–4:45pm.

Where is the Antibody Engineering 2026 program?

This guide lists every organization on the Antibody Engineering 2026 program with its sessions; the full program is on the official website.

How do I register for Antibody Engineering 2026?

Fees and registration are on the organizer's registration page.

What conference is this?

Antibody Engineering & Therapeutics is an annual meeting on antibody discovery and engineering, run with The Antibody Society and held December 13–16, 2026 at the Marriott Marquis San Diego Marina. It brings together antibody discovery, protein engineering and developability scientists from pharma, biotech and academia with the discovery-platform, reagent and instrument companies that serve them, across tracks on in vitro and in vivo discovery, bispecifics and multispecifics, cell engagers, antibody–drug conjugates, antibody interfaces and domains, difficult targets, and uses beyond oncology.

What is in this guide?

Every organization we can place at Antibody Engineering 2026: 131 speakers from the public program (134 sessions) rolled up to their companies and institutions, plus the 85 sponsors and exhibitors from the public directory with their booth numbers where published — 168 organizations in one list. Speakers appear as job titles, never by name.

How are organizations typed?

By the role an organization plays in antibody discovery and development: drug developers (large pharma and biotech), then the companies around them — CROs and CDMOs, discovery platforms, reagents, instruments and analytics, software and AI, consulting and other services — and academic, government and non-profit bodies. The topic filters come from the track a session sits in and from each session’s own title and abstract.

How current is it?

Pulled from the public agenda, speaker list and sponsor directory on November 10, 2026. Exhibit-hall hours are the first and last exhibit-hall activity on the public agenda.

Browse Antibody Engineering 2026 by

Exhibit hall

Organizations with their own page

106 organizations — every exhibitor and every organization with 2 or more presentations.

Not affiliated with or endorsed by Antibody Engineering & Therapeutics, its organizers or The Antibody Society. Submit a correction